Anavex Life Sciences Corp. beat EPS estimates 50% of the time across 4 reported quarters (2 beats, 2 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q32026 FY2026 | $-0.08 | $-0.16 | -100.0% | Miss |
| Q22026 FY2026 | $-0.08 | $-0.06 | +25.0% | Beat |
| Q22026 FY2026 | $-0.07 | $-0.13 | -85.7% | Miss |
| Q32026 FY2026 | $-0.07 | — | — | Miss |
| Q12026 FY2026 | $-0.10 | $-0.06 | +40.0% | Beat |
Back to AVXL overview · AVXL holders · AVXL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.